|
|||||
|
|
| 索拉非尼在肝癌治疗中的应用 | |
| 引用本文： | 张传海,荚卫东. 索拉非尼在肝癌治疗中的应用[J]. 临床药物治疗杂志, 2012, 10(3): 24-26 |
| 作者姓名： | 张传海 荚卫东 |
| 作者单位： | 安徽省立医院肝脏外科、肝胆胰外科安徽省重点实验室,合肥,230001 |
| 摘 要： | 肝细胞癌是最常见的恶性肿瘤之一,死亡率高,预后不理想。近年来,应用分子靶向药物治疗肝癌取得重大突破,特别是多靶点、多激酶抑制药索拉非尼在肝癌的治疗取得的成功。 |
| 关 键 词： | 肝癌 肝细胞 索拉非尼 |
Sorafenib for the treatment of hepatocellular carcinoma |
|
| Zhang Chuan-hai , Jia Wei-dong. Sorafenib for the treatment of hepatocellular carcinoma[J]. Clinical Medication JOurnal, 2012, 10(3): 24-26 | |
| Authors: | Zhang Chuan-hai Jia Wei-dong |
| Affiliation: | Zhang Chuan-hai Jia Wei-dong |
| Abstract: | Hepatocellular carcinoma is one of the most malignant tumors in the world. HCC patients often have a high death rate and a poor clinical outcome. In recent years, targeted molecular therapy, an important breakthrough in tumor therapies, has achieved success in the treatment of hepatocellular carcinoma. Multi-target, multi-kinase inhibitor sorafenib gets success in hepatocellular carcinoma treatment. |
| Keywords: | |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |